Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Pass Below 50 Day Moving Average - Should You Sell?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $8.60 and traded as low as $7.85. Aurinia Pharmaceuticals shares last traded at $7.97, with a volume of 984,232 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $10.00.

Aurinia Pharmaceuticals Price Performance

The company has a market cap of $1.12 billion, a P/E ratio of -51.93 and a beta of 1.22. The firm's 50-day moving average is $8.52 and its two-hundred day moving average is $7.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Northern Trust Corp increased its stake in Aurinia Pharmaceuticals by 5.9% during the fourth quarter. Northern Trust Corp now owns 1,054,365 shares of the biotechnology company's stock worth $9,468,000 after acquiring an additional 58,676 shares during the last quarter. Quarry LP bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at approximately $108,000. Oxford Asset Management LLP purchased a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $97,000. Susquehanna Fundamental Investments LLC bought a new stake in Aurinia Pharmaceuticals in the fourth quarter worth $90,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Aurinia Pharmaceuticals by 19.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company's stock worth $468,000 after buying an additional 8,350 shares during the last quarter. Institutional investors own 36.83% of the company's stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.